Novel Mutations in CEBPA in Korean Patients with Acute Myeloid Leukemia with a Normal Karyotype
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Mutations in the transcription factor CCAAT/enhancer binding protein α gene (CEBPA) are found in 5-14% of the patients with AML and have been associated with a favorable clinical outcome. In this study, we aimed to assess the frequencies and characteristics of mutations in CEBPA. Between 2006 and 2009, CEBPA mutations were assessed using archival DNA samples obtained from 30 consecutive adult patients diagnosed with AML with a normal karyotype at our institution. CEBPA mutations were detected using direct sequencing analyses. These mutations were detected and described with reference to GenBank Accession No. NM_004364.3. In our series, CEBPA mutations were detected in 4 patients (13.3%). These mutations occurred as double mutations in all 4 patients. Among the 8mutant alleles, 5 were novel (c.179_180dupCG, c.50_53delGCCA, c.178_182delACGTinsTTT,c.243_244insGTCG, and c.923_924insCTC). The frequency of occurrence of CEBPA mutations in Korean patients with AML is comparable to that in previous reports. Long-term follow-up data from a larger series of patients with comprehensive molecular profiling are needed to delineate the prognostic implications.
Abstract
Mutations in the transcription factor CCAAT/enhancer binding protein α gene (CEBPA) are found in 5-14% of the patients with AML and have been associated with a favorable clinical outcome. In this study, we aimed to assess the frequencies and characteristics of mutations in CEBPA. Between 2006 and 2009, CEBPA mutations were assessed using archival DNA samples obtained from 30 consecutive adult patients diagnosed with AML with a normal karyotype at our institution. CEBPA mutations were detected using direct sequencing analyses. These mutations were detected and described with reference to GenBank Accession No. NM_004364.3. In our series, CEBPA mutations were detected in 4 patients (13.3%). These mutations occurred as double mutations in all 4 patients. Among the 8mutant alleles, 5 were novel (c.179_180dupCG, c.50_53delGCCA, c.178_182delACGTinsTTT,c.243_244insGTCG, and c.923_924insCTC). The frequency of occurrence of CEBPA mutations in Korean patients with AML is comparable to that in previous reports. Long-term follow-up data from a larger series of patients with comprehensive molecular profiling are needed to delineate the prognostic implications.
참고문헌 (29)
- Byrd JC, "Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)", Blood, 100, pp.4325~4336 (2002)
- Grimwade D, "The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties", Blood, 92, pp.2322~2333 (1998)
- Mrozek K, "Cytogenetics in acute leukemia", Blood Rev, 18, pp.115~136 (2004)
- Estey E, "Acute myeloid leukaemia", Lancet, 368, pp.1894~1907 (2006)
- Lowenberg B, "Acute myeloid leukemia and acute promyelocytic leukemia", Hematology Am Soc Hematol Educ Program, pp.82~101 (2003)
- Schlenk RF, "Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia", New Engl J Med, 358, pp.1909~1918 (2008)
- Scholl S, "Clinical implications of molecular genetic aberrations in acute myeloid leukemia", J Cancer Res Clin Oncol, 135, pp.491~505 (2009)
- Ley TJ, "DNMT3A mutations in acute myeloid leukemia", N Engl J Med, 363, pp.2424~2433 (2010)
- Abbas S, "Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value", Blood, 116, pp.2122~2126 (2010)
- Metzeler KH, "TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study", J Clin Oncol, 29, pp.1373~1381 (2011)
- Pabst T, "Complexity of CEBPA dysregulation in human acute myeloid leukemia", Clin Cancer Res, 15, pp.5303~5307 (2009)
- Renneville A, "The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication", Blood, 113, pp.5090~5093 (2009)
- Wouters BJ, "Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome", Blood, 113, pp.3088~3091 (2009)
- Dufour A, "Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome", J Clin Oncol, 28, pp.570~577 (2010)
- Taskesen E, "Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity", Blood, 117, pp.2469~2475 (2011)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed" (2008), International Agency for Research on Cancer
- Pabst T, "Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis", Br J Cancer, 100, pp.1343~1346 (2009)
- Lin LI, "Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells", Clin Cancer Res, 11, pp.1372~1379 (2005)
- Fuchs O, "CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma", Blood Cells Mol Dis, 40, pp.401~405 (2008)
- Ishikawa Y, "Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia", Eur J Haematol, 83, pp.90~98 (2009)
- Pabst T, "Dominant-negative mutations of CEBPA, encoding CCAAT", enhancer binding protein-alpha (C, Nat Genet, pp.2001, 27[DOI]
- Snaddon J, "Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2", Genes Chromosomes Cancer, 37, pp.72~78 (2003)
- Barjesteh van Waalwijk van Doorn-Khosrovani S, "Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML", Hematol J, 4, pp.31~40 (2003)
- Gombart AF, "Mutations in the gene encoding the transcription factor CCAAT", enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias, 2002, pp.99, 1332~1340
- Frohling S, "CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations", J Clin Oncol, 22, pp.624~633 (2004)
- Resende C, "Genetic changes of CEBPA in cancer: mutations or polymorphisms?", J Clin Oncol, 25, pp.2493~2494 (2007)
- Wouters BJ, "A recurrent inframe insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profilingbased clustering of AML", Blood, 109, pp.389~390 (2007)
- Szankasi P, "Combined testing for CCAAT", enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features, 2011, pp.35, 200~207
- Lin TC, "CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia", Leukemia, 25, pp.32~40 (2011)